Zonegran Postmarketing Skin/Renal AEs To Be Considered Unlabeled Events

Elan should consider any postmarketing reports of allergic, skin, blood disorder and renal reactions with its new antiepileptic Zonegran to be unlabeled events, FDA told the company.